When Metformin Is Not Enough: Pros And Cons Of Sglt2 And Dpp-4 Inhibitors As A Second Line Therapy.
Generate a file for use with external citation management software. Diabetes Metab Res Rev. 2018 Jan 10. doi: 10.1002/dmrr.2981. [Epub ahead of print] When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Department of Internal Medicine, Unit of Metabolic Disease, University of Padova, Padova, Italy. Department of Endocrinology and Nutrition, University of Oviedo, Oviedo, Spain. Endocrinology and Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain. Metabolism Unit, Instituto de Investigacin Sanitaria del Principado de Asturias (ISPA), Asturias, Spain. Internal Medicine/Endocrinology and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA. The newer oral therapies for type 2 diabetes mellitus, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors, have advantages over older agents. Dipeptidyl peptidase-4 inhibitors are weight neutral and have few adverse effects. Sodium glucose cotransporter 2 inhibitors have additional benefits: weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. Sodium glu Continue reading >>